Glaukos (GKOS) Net Income towards Common Stockholders (2014 - 2026)
Glaukos (GKOS) posted quarterly Net Income towards Common Stockholders of -$18.4 million for Q2 2026, up 6.29% year-over-year from -$17.3 million in Q2 2025, and up 6.96% quarter-over-quarter from -$19.8 million in Q1 2026.
Glaukos (GKOS) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Glaukos (GKOS) has reported Net Income towards Common Stockholders for 13 consecutive years, with -$18.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders rose 6.29% year-over-year to -$18.4 million; the TTM figure through Jun 2026 stood at -$157.5 million (down 147.36% YoY), while the FY2025 annual figure was -$157.1 million, down 33.98% from the prior year.
- Net Income towards Common Stockholders improved to -$18.4 million in Q2 2026 per GKOS's latest filing, from -$19.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5.4 million in Q1 2022 and bottomed at -$103.1 million in Q4 2025.
- Historically, Net Income towards Common Stockholders has averaged -$29.2 million across 5 years, with a median of -$24.5 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 132.65% — and 2025, when it plunged 2219.67%.
- Glaukos' Net Income towards Common Stockholders stood at -$34.3 million in 2022, then soared by 64.44% to -$12.2 million in 2023, then jumped by 63.62% to -$4.4 million in 2024, then slumped by 2219.67% to -$103.1 million in 2025, then soared by 82.13% to -$18.4 million in 2026.
- Business Quant data shows GKOS's Net Income towards Common Stockholders at -$18.4 million in Q2 2026, -$19.8 million in Q1 2026, and -$103.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Glaukos | 11.03 Bn | 10.92 Bn | 151.59 Mn | -18.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.42 Mn |
| Mar 31, 2026 | -19.80 Mn |
| Dec 31, 2025 | -103.06 Mn |
| Sep 30, 2025 | -16.23 Mn |
| Jun 30, 2025 | -19.66 Mn |
| Mar 31, 2025 | -18.15 Mn |
| Dec 31, 2024 | -4.44 Mn |
| Sep 30, 2024 | -21.43 Mn |
| Jun 30, 2024 | -50.55 Mn |
| Mar 31, 2024 | -40.86 Mn |
| Dec 31, 2023 | -12.21 Mn |
| Sep 30, 2023 | -30.44 Mn |
| Jun 30, 2023 | -32.81 Mn |
| Mar 31, 2023 | -34.63 Mn |
| Dec 31, 2022 | -34.35 Mn |
| Sep 30, 2022 | -27.58 Mn |
| Jun 30, 2022 | -45.54 Mn |
| Mar 31, 2022 | 5.38 Mn |
| Dec 31, 2021 | -23.98 Mn |
| Sep 30, 2021 | 6.23 Mn |